Procedures and controls utilized within the Quality Control (QC) Laboratory in support of drug substance release and(b) (4)testing are deficient.
Inspection Record
Samsung Biologics Co., Ltd. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Failure to follow established procedures for reporting and implementing changes to an approved application.
Procedures implemented to prevent cross-contamination of drug substances during product change over (PCO) operations were not followed.
The responsibilities and procedures applicable to the quality control unit were not followed.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- ROSLIN CELL THERAPIES LIMITED2025-01-21 · US FDASimilar to finding 4 The responsibilities and procedures applicable to the quality control unit are not fully followed.
- Sterigenics US , LLC2022-08-23 · US FDASimilar to finding 4 The responsibilities and procedures applicable to the quality control unit are not fully followed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.